PR Newswire SAN ANTONIO, Dec. 10, 2024 Expansion Brings New Principal Investigators, Expanded Site Resources, and Accelerated Trial Initiation to Support Breakthrough Blood Cancer Therapies SAN ANTONIO, Dec. 10, 2024 /PRNewswire/ -- The ...
PR Newswire ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and ...
PR Newswire LEXINGTON, Mass., Dec. 10, 2024 LEXINGTON, Mass., Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small ...
PR Newswire HENDERSON, Nev., Dec. 10, 2024 HENDERSON, Nev., Dec. 10, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which ...
PR Newswire LEHI, Utah, Dec. 10, 2024 LEHI, Utah, Dec. 10, 2024 /PRNewswire/ -- Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today ...
PR Newswire NEW YORK, Dec. 10, 2024 The Five Most Common Types of Cancer in Adults Aged 18 to 49 in 2023 Were Skin, Breast, Thyroid and Other Endocrine Glands, Digestive Organs and Female Genital Organs NEW YORK, Dec. 10, 2024 ...
PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 10, 2024 SOUTH SAN FRANCISCO, Calif., Dec. 10, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and ...
PR Newswire SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 9, 2024 SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 9, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the ...
PR Newswire BUFFALO, N.Y., Dec. 9, 2024 About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that ...
PR Newswire INDIANAPOLIS, Dec. 9, 2024 Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab Pirtobrutinib ...
Discover how a gut-on-chip device predicts melanoma patients' response to immunotherapy by simulating intestinal inflammation and microbiota interaction.
New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.
Vitamin E succinate has been found to inhibit tumor growth and enhance the effectiveness of immunotherapy by targeting critical elements of tumor development.
Discover how a simple saliva test offers a painless and reliable method for early oral cancer detection, potentially replacing invasive biopsies.
Discover why cancer cases have doubled in India since 1990. Learn about causes, prevention, and advancements in treatment.
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2025
Careers